ETTX · Entasis Therapeutics Holdings Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.99M | - | $9.28M | $9.99M | $9.37M | - | $9.39M | $10.24M | $11.62M | - |
| SG&A | $4.94M | - | $4.32M | $3.31M | $3.31M | - | $3.21M | $3.24M | $3.78M | - |
| Total Operating Expenses | $15.93M | - | $13.60M | $13.30M | $12.68M | - | $12.60M | $13.48M | $15.40M | - |
| D&A | $24.0K | - | - | - | $28.0K | - | - | - | $37.0K | - |
| Operating Income | ($15.93M) | - | ($13.60M) | ($13.30M) | ($12.68M) | - | ($12.60M) | ($13.48M) | ($15.40M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($15.26M) | - | ($12.39M) | ($12.03M) | ($10.70M) | - | ($11.13M) | ($13.40M) | ($15.27M) | - |
| EPS - Basic | ($0.29) | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.29) | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.55M | $32.31M | $44.12M | $56.41M | $44.94M | $53.25M | $61.19M | $50.77M | $17.45M | $16.03M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.78M | $1.18M | $1.13M | $1.04M | $434.0K | $660.0K | $815.0K | $1.60M | $1.15M | $1.30M |
| Current Assets | $39.88M | $39.81M | $49.75M | $62.42M | $51.55M | $60.13M | $68.40M | $54.75M | $32.78M | $49.01M |
| Total Assets | $44.09M | $40.92M | $50.77M | $63.56M | $52.83M | $61.56M | $69.96M | $56.46M | $34.66M | $51.03M |
| Current Liabilities | $24.14M | $9.71M | $9.35M | $10.14M | $8.03M | $8.56M | $6.86M | $6.16M | $5.78M | $7.56M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $27.44M | $9.71M | $9.53M | $10.51M | $8.57M | $9.27M | $7.73M | $7.18M | $6.96M | $8.88M |
| Stockholders' Equity | $16.65M | $31.21M | $41.23M | $53.06M | $44.26M | $52.29M | $62.24M | $49.29M | $27.70M | $42.16M |
| Retained Earnings | ($246.86M) | ($231.60M) | ($219.58M) | ($207.19M) | ($195.16M) | ($184.46M) | ($173.75M) | ($162.62M) | ($149.22M) | ($133.96M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.75M) | - | - | - | ($10.10M) | - | - | - | ($13.57M) | - |
| Investing Cash Flow | ($9.0K) | - | - | - | ($11.0K) | - | - | - | $15.00M | - |
| Financing Cash Flow | $15.00M | - | - | - | $1.80M | - | - | - | ($16.0K) | - |
| CapEx | $9.0K | - | - | - | $11.0K | - | - | - | - | - |
| Free Cash Flow | ($13.76M) | - | - | - | ($10.11M) | - | - | - | - | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.90 | - | - | - | 0.94 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -34.6% | - | -24.4% | -18.9% | -20.3% | - | -15.9% | -23.7% | -44.0% | - |
| Return on equity | -91.7% | - | -30.0% | -22.7% | -24.2% | - | -17.9% | -27.2% | -55.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.65 | 4.10 | 5.32 | 6.15 | 6.42 | 7.02 | 9.97 | 8.89 | 5.67 | 6.49 |
| Quick ratio | 1.65 | 4.10 | 5.32 | 6.15 | 6.42 | 7.02 | 9.97 | 8.89 | 5.67 | 6.49 |
| Cash ratio | 1.39 | 3.33 | 4.72 | 5.56 | 5.59 | 6.22 | 8.92 | 8.25 | 3.02 | 2.12 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.65 | 1.31 | 1.23 | 1.20 | 1.19 | 1.18 | 1.12 | 1.15 | 1.25 | 1.21 |
| Liabilities / Assets | 0.62 | 0.24 | 0.19 | 0.17 | 0.16 | 0.15 | 0.11 | 0.13 | 0.20 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -25.6% | - | -8.0% | 1.4% | 17.7% | - | -205.3% | -91.8% | -30.9% | - |
| Net income growth (YoY) | -42.6% | - | -11.3% | 10.2% | 29.9% | - | -219.5% | -133.7% | -18.0% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -36.1% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.4% | -40.3% | -33.7% | 7.7% | 59.7% | 24.0% | 13.4% | -14.8% | -60.7% | -49.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Entasis Therapeutics Holdings Inc. against the 5 most active filers in the same SIC group.